Have a feature idea you'd love to see implemented?
Let us know!
LUMO Lumos Pharma Inc
Price (delayed)
$4.35
Market cap
$35.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.43
Enterprise value
$18.99M
Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management
Highlights
The debt has grown by 30% year-on-year but it has declined by 13% since the previous quarter
LUMO's EPS is down by 16% year-on-year but it is up by 3.5% since the previous quarter
The equity has plunged by 76% YoY and by 41% from the previous quarter
LUMO's quick ratio has dropped by 56% year-on-year and by 35% since the previous quarter
Key stats
What are the main financial stats of LUMO
Market
Valuations
Earnings
Shares outstanding
8.12M
Market cap
$35.34M
Enterprise value
$18.99M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.44
Price to sales (P/S)
23.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.78
Revenue
$1.49M
EBIT
-$35.75M
EBITDA
-$35.72M
Free cash flow
-$34.49M
Per share
Balance sheet
Liquidity
EPS
-$4.43
Free cash flow per share
-$4.25
Book value per share
$1.27
Revenue per share
$0.18
TBVPS
$2.63
Total assets
$21.36M
Total liabilities
$11.08M
Debt
$449,000
Equity
$10.28M
Working capital
$15.96M
Debt to equity
0.04
Current ratio
4.23
Quick ratio
3.44
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-2,403.7%
Gross margin
100%
Net margin
-2,405.7%
Operating margin
-2,531.7%
Return on assets
-103.8%
Return on equity
-158%
Return on invested capital
-2,188.2%
Return on capital employed
-217.7%
Return on sales
-2,405.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LUMO stock price
How has the Lumos Pharma stock price performed over time
Intraday
10.13%
1 week
8.48%
1 month
15.69%
1 year
15.38%
YTD
36.79%
QTD
12.4%
Financial performance
How have Lumos Pharma's revenue and profit performed over time
Revenue
$1.49M
Gross profit
$1.49M
Operating income
-$37.62M
Net income
-$35.75M
Gross margin
100%
Net margin
-2,405.7%
The net margin has dropped by 69% year-on-year
LUMO's operating margin has shrunk by 66% YoY but it is up by 2.1% QoQ
The revenue has contracted by 33% YoY and by 2.6% from the previous quarter
LUMO's gross profit is down by 33% YoY and by 2.6% from the previous quarter
Growth
What is Lumos Pharma's growth rate over time
Valuation
What is Lumos Pharma stock price valuation
P/E
N/A
P/B
3.44
P/S
23.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.78
LUMO's EPS is down by 16% year-on-year but it is up by 3.5% since the previous quarter
The P/B is 160% more than the last 4 quarters average of 1.2
The equity has plunged by 76% YoY and by 41% from the previous quarter
The P/S is 96% lower than the 5-year quarterly average of 524.5 but 55% higher than the last 4 quarters average of 13.9
The revenue has contracted by 33% YoY and by 2.6% from the previous quarter
Efficiency
How efficient is Lumos Pharma business performance
LUMO's ROE has shrunk by 178% YoY and by 32% QoQ
LUMO's ROIC has shrunk by 176% QoQ
LUMO's ROA has dropped by 122% year-on-year and by 21% since the previous quarter
LUMO's return on sales has dropped by 68% year-on-year
Dividends
What is LUMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LUMO.
Financial health
How did Lumos Pharma financials performed over time
The company's total assets is 93% higher than its total liabilities
The company's total assets has shrunk by 62% YoY and by 24% QoQ
LUMO's quick ratio has dropped by 56% year-on-year and by 35% since the previous quarter
The debt is 96% smaller than the equity
The equity has plunged by 76% YoY and by 41% from the previous quarter
Lumos Pharma's debt to equity has increased by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.